Volition Publishes Paper On Capture-Seq Liquid Biopsy

VNRX Volition — first peer-reviewed paper published on new Capture-Seq liquid biopsy technology — Isolates >99% pure circulating tumor DNA from plasma, tackling the core problem of healthy DNA drowning out cancer signal — Detected 49/49 cancers in first validation cohort, 13/14 in second blinded cohort — Targets $23B multi-cancer early detection market plus $13B minimal residual disease market — In active discussions with diagnostic companies on licensing